Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

458 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ. van Essen M, et al. Among authors: krenning ep. Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8. doi: 10.1007/s00259-007-0688-7. Epub 2008 Jan 11. Eur J Nucl Med Mol Imaging. 2008. PMID: 18188559 Free PMC article.
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A. Delpassand ES, et al. Among authors: krenning ep. Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113. Pancreas. 2014. PMID: 24632546 Clinical Trial.
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ. Bergsma H, et al. Among authors: krenning ep. Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):867-81. doi: 10.1016/j.bpg.2013.01.004. Best Pract Res Clin Gastroenterol. 2012. PMID: 23582925
458 results